Company intelligence / Profile preview

Scandinavian Biopharma Distribution AB

Solna, Stockholm, Swedenscandinavianbiopharma.se ↗

Ownership: Private
Employees: ~29
Development stage: Commercial

Overview

The company has a successful distribution business while also developing the first vaccine for protection against diarrhea caused by ETEC. They recently signed a joint procurement with EU commission to supply diphtheria antitoxin.

Therapeutic areas: Infectious Diseases
Modalities: VaccinesImmunoglobulins
Industry: Biotech

Drug pipeline

2 assets

tafenoquine

Commercial

Indications: Malaria prevention, COVID-19, Fungal infections, Babesiosis

1 more asset in the full pipeline.

Request access →

Partnerships

AJ VaccinesKedrionNeoviiFlynn PharmaEmergent BiosolutionsTravel Health GroupUniversity of GothenburgPATHUSAMMDAEuropean Commission's HERA

Beyond the preview

Go deeper on Scandinavian Biopharma Distribution AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Scandinavian Biopharma Distribution AB.

Explore the full profile